Skip to main content
XNCR
NASDAQ Life Sciences

Xencor Adopts New Executive Severance Policy for Key Officers

Analysis by Wiseek.aiReviewed by Editorial Team
Sentiment info
Neutral
Importance info
7
Price
$13.1
Mkt Cap
$960.736M
52W Low
$6.92
52W High
$18.69
Market data snapshot near publication time

summarizeSummary

Xencor Inc. has adopted a new Executive Severance Policy providing benefits, including salary, COBRA, and equity acceleration, to eligible executives upon certain terminations, particularly around a change in control.


check_boxKey Events

  • New Severance Policy Adopted

    Xencor Inc. adopted a new Executive Severance Policy on April 23, 2026, formalizing severance benefits for certain executives.

  • Eligible Executives

    The policy covers Vice Presidents, Senior Vice Presidents, and Executive Vice Presidents, but specifically excludes the Chief Executive Officer.

  • Standard Termination Benefits

    For terminations without cause or resignations for good reason (outside a change in control period), eligible executives may receive 9-15 months of base salary and COBRA premiums, depending on their role.

  • Change in Control Benefits

    During a change in control period, eligible executives receive additional benefits, including bonus compensation and accelerated vesting of all outstanding unvested stock options and equity awards, subject to a "double-trigger" requirement.


auto_awesomeAnalysis

The adoption of a new Executive Severance Policy clarifies the terms for severance benefits for Xencor's Vice Presidents, Senior Vice Presidents, and Executive Vice Presidents (excluding the CEO). This policy aims to provide stability and retention incentives for key management, especially in the event of a change in control, where a "double-trigger" mechanism ensures benefits are paid only upon both a change in control and a subsequent involuntary termination or resignation for good reason. While a standard governance practice, establishing such a comprehensive policy is an important step in formalizing executive compensation and risk management.

At the time of this filing, XNCR was trading at $13.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $960.7M. The 52-week trading range was $6.92 to $18.69. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed XNCR - Latest Insights

XNCR
Apr 27, 2026, 4:03 PM EDT
Filing Type: DEFA14A
Importance Score:
8
XNCR
Apr 27, 2026, 4:02 PM EDT
Filing Type: DEF 14A
Importance Score:
7
XNCR
Apr 27, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
XNCR
Mar 09, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
XNCR
Mar 04, 2026, 4:03 PM EST
Source: Wiseek News
Importance Score:
8
XNCR
Mar 04, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
8
XNCR
Feb 25, 2026, 4:02 PM EST
Filing Type: 10-K
Importance Score:
8
XNCR
Feb 25, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
8
XNCR
Jan 08, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7